{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:22:39Z","timestamp":1772007759239,"version":"3.50.1"},"reference-count":118,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Epstein-Barr virus (EBV) is closely associated with several lymphomas (endemic Burkitt lymphoma, Hodgkin lymphoma and nasal NK\/T-cell lymphoma) and epithelial cancers (nasopharyngeal carcinoma and gastric carcinoma). To maintain its persistence in the host cells, the virus manipulates the ubiquitin-proteasome system to regulate viral lytic reactivation, modify cell cycle checkpoints, prevent apoptosis and evade immune surveillance. In this review, we aim to provide an overview of the mechanisms by which the virus manipulates the ubiquitin-proteasome system in EBV-associated lymphoid and epithelial malignancies, to evaluate the efficacy of proteasome inhibitors on the treatment of these cancers and discuss potential novel viral-targeted treatment strategies against the EBV-associated cancers.<\/jats:p>","DOI":"10.3390\/v9110352","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T11:23:20Z","timestamp":1511263400000},"page":"352","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors"],"prefix":"10.3390","volume":"9","author":[{"given":"Kwai","family":"Hui","sequence":"first","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China"},{"name":"Center for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kam","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China"},{"name":"Center for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1089-5325","authenticated-orcid":false,"given":"Alan","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China"},{"name":"Center for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.virol.2008.10.005","article-title":"Manipulation of the ubiquitin-proteasome pathway by small DNA tumor viruses","volume":"384","author":"Blanchette","year":"2009","journal-title":"Virology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2741\/4254","article-title":"The role of the ubiquitin-proteasome pathway in cancer development and treatment","volume":"19","author":"Ding","year":"2014","journal-title":"Front. Biosci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-5793(97)01480-4","article-title":"Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53","volume":"420","author":"Honda","year":"1997","journal-title":"FEBS Lett."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"18562","DOI":"10.1073\/pnas.0503886102","article-title":"Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase","volume":"102","author":"Knight","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"18923","DOI":"10.1074\/jbc.M109.015123","article-title":"Phosphorylation of P27KIP1 by Epstein-Barr virus protein kinase induces its degradation through SCFSKP2 ubiquitin ligase actions during viral lytic replication","volume":"284","author":"Iwahori","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Full, F., Hahn, A.S., Grosskopf, A.K., and Ensser, A. (2017). Gammaherpesviral tegument proteins, PML-nuclear bodies and the ubiquitin-proteasome system. Viruses, 9.","DOI":"10.3390\/v9100308"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/386463a0","article-title":"Structure of 20s proteasome from yeast at 2.4 \u00c5 resolution","volume":"386","author":"Groll","year":"1997","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0969-2126(02)00748-7","article-title":"The structure of the mammalian 20s proteasome at 2.75 \u00c5 resolution","volume":"10","author":"Unno","year":"2002","journal-title":"Structure"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.tibs.2012.11.009","article-title":"Functions of the 19S complex in proteasomal degradation","volume":"38","author":"Liu","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.1016\/S0021-9258(20)82050-X","article-title":"Components of ubiquitin-protein ligase system. Resolution, affinity purification and role in protein breakdown","volume":"258","author":"Hershko","year":"1983","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrm2780","article-title":"Building ubiquitin chains: E2 enzymes at work","volume":"10","author":"Ye","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"26817","DOI":"10.1074\/jbc.M404020200","article-title":"Rad23 and Rpn10 serve as alternative ubiquitin receptors for the proteasome","volume":"279","author":"Elsasser","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature06926","article-title":"Proteasome subunit Rpn13 is a novel ubiquitin receptor","volume":"453","author":"Husnjak","year":"2008","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0092-8674(00)80574-7","article-title":"A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly","volume":"96","author":"Koegl","year":"1999","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/363552a0","article-title":"A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation","volume":"363","author":"Michalek","year":"1993","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"12616","DOI":"10.1073\/pnas.94.23.12616","article-title":"Inhibition of ubiquitin\/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1","volume":"94","author":"Levitskaya","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.virol.2011.01.026","article-title":"The central repeat domain 1 of kaposi\u2019s sarcoma-associated herpesvirus (KSHV) latency associated-nuclear antigen 1 (LANA1) prevents cis MHC class I peptide presentation","volume":"412","author":"Kwun","year":"2011","journal-title":"Virology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/JVI.02183-15","article-title":"The missing link in Epstein-Barr virus immune evasion: The BDLF3 gene induces ubiquitination and downregulation of major histocompatibility complex class I (MHC-I) and MHC-II","volume":"90","author":"Quinn","year":"2015","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1073\/pnas.140129797","article-title":"Kaposi's sarcoma\u2014Associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis","volume":"97","author":"Coscoy","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nature03464","article-title":"IRF-7 is the master regulator of type-I interferon-dependent immune responses","volume":"434","author":"Honda","year":"2005","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.immuni.2010.11.027","article-title":"The ubiquitin E3 ligase RAUL negatively regulates type I interferon through ubiquitination of the transcription factors IRF7 and IRF3","volume":"33","author":"Yu","year":"2010","journal-title":"Immunity"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1073\/pnas.1019599108","article-title":"Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing P16INK4A and p14ARF expression","volume":"108","author":"Maruo","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1073\/pnas.0801053105","article-title":"Ebv-encoded EBNA-6 binds and targets MRS18\u20132 to the nucleus, resulting in the disruption of PRB-E2F1 complexes","volume":"105","author":"Kashuba","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Banerjee, S., Lu, J., Cai, Q., Sun, Z., Jha, H.C., and Robertson, E.S. (2014). EBNA3C augments PIM-1 mediated phosphorylation and degradation of p21 to promote B-cell proliferation. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004304"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1128\/MCB.25.5.1749-1763.2005","article-title":"SCFSKP2 complex targeted by Epstein-Barr virus essential nuclear antigen","volume":"25","author":"Knight","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pei, Y., Banerjee, S., Jha, H.C., Sun, Z., and Robertson, E.S. (2017). An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006500"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1073\/pnas.0813237106","article-title":"Regulation of cyclin a protein in meiosis and early embryogenesis","volume":"106","author":"Vardy","year":"2009","journal-title":"Proc. Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/j.1460-2075.1992.tb05135.x","article-title":"Cyclin a is required at two points in the human cell cycle","volume":"11","author":"Pagano","year":"1992","journal-title":"Embo. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/emboj\/18.3.654","article-title":"Modulation of p27(KIP1) levels by the cyclin encoded by kaposi\u2019s sarcoma-associated herpesvirus","volume":"18","author":"Mann","year":"1999","journal-title":"EMBO J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/emboj\/18.3.644","article-title":"Degradation of p27(KIP) CDK inhibitor triggered by kaposi\u2019s sarcoma virus cyclin-CDK6 complex","volume":"18","author":"Ellis","year":"1999","journal-title":"EMBO J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4161\/cbt.10.10.13923","article-title":"Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention","volume":"10","author":"Saha","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7557","DOI":"10.1038\/sj.onc.1207120","article-title":"Epstein-Barr virus\u2014Encoded latent infection membrane protein 1 regulates the processing of p100 NF-\u03baB2 to p52 via an IKK\u03b3\/nemo-independent signalling pathway","volume":"22","author":"Eliopoulos","year":"2003","journal-title":"Oncogene"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"29987","DOI":"10.1074\/jbc.M303977200","article-title":"Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP\/USP7","volume":"278","author":"Holowaty","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/JVI.02408-08","article-title":"Epstein-Barr virus nuclear antigen 3C augments MDM2-mediated p53 ubiquitination and degradation by deubiquitinating MDM2","volume":"83","author":"Saha","year":"2009","journal-title":"J. Virol"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1128\/JVI.80.5.2257-2266.2006","article-title":"Inhibition of the ATM\/p53 signal transduction pathway by kaposi\u2019s sarcoma-associated herpesvirus interferon regulatory factor 1","volume":"80","author":"Shin","year":"2006","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1128\/JVI.02353-08","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway","volume":"83","author":"Lee","year":"2009","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","article-title":"Proteasome inhibitors: From research tools to drug candidates","volume":"8","author":"Kisselev","year":"2001","journal-title":"Chem. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States food and drug administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2011.11.005","article-title":"Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A","volume":"317","author":"Huang","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00277-010-1022-1","article-title":"Proteasome inhibitor bortezomib targeted tumor\u2014Endothelial cell interaction in T-cell leukemia\/lymphoma","volume":"90","author":"Shi","year":"2011","journal-title":"Ann. Hematol."},{"key":"ref_42","unstructured":"Rickinson, A.B., and Kieff, E. (2007). Epstein-barr Virus, Lippincott Williams and Wilkins. [5th ed.]."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1128\/jvi.68.6.3491-3498.1994","article-title":"Epstein-Barr virus nuclear antigen EBNA3C\/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells","volume":"68","author":"Allday","year":"1994","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Saha, A., Halder, S., Upadhyay, S.K., Lu, J., Kumar, P., Murakami, M., Cai, Q., and Robertson, E.S. (2011). Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1001275"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Hertle, M.L., Popp, C., Petermann, S., Maier, S., Kremmer, E., Lang, R., Mages, J., and Kempkes, B. (2009). Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000506"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2217\/fmb.12.147","article-title":"Impact of ebv essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis","volume":"8","author":"Saha","year":"2013","journal-title":"Future Microbiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"19500","DOI":"10.1073\/pnas.0604919104","article-title":"Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells","volume":"103","author":"Maruo","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cai, Q., Guo, Y., Xiao, B., Banerjee, S., Saha, A., Lu, J., Glisovic, T., and Robertson, E.S. (2011). Epstein-Barr virus nuclear antigen 3C stabilizes gemin3 to block p53-mediated apoptosis. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002418"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Skalska, L., White, R.E., Franz, M., Ruhmann, M., and Allday, M.J. (2010). Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CTBP. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000951"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/sj.onc.1207253","article-title":"The EBNA-3 gene family proteins disrupt the G2\/M checkpoint","volume":"23","author":"Krauer","year":"2004","journal-title":"Oncogene"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1128\/JVI.00053-07","article-title":"The ATM\/ATR signaling effector CHK2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2\/M cell cycle block","volume":"81","author":"Choudhuri","year":"2007","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/sj.onc.1203327","article-title":"Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis","volume":"19","author":"Parker","year":"2000","journal-title":"Oncogene"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1128\/MCB.20.4.1344-1360.2000","article-title":"Epstein-Barr virus suppresses a G(2)\/M checkpoint activated by genotoxins","volume":"20","author":"Wade","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"White, R.E., Groves, I.J., Turro, E., Yee, J., Kremmer, E., and Allday, M.J. (2010). Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013979"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e925","DOI":"10.1038\/cddis.2013.440","article-title":"Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2\/M transition and MCL-1 degradation","volume":"4","author":"Rapino","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_56","first-page":"76","article-title":"Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1","volume":"41","author":"Hong","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/sj.leu.2404528","article-title":"Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD30+ anaplastic large cell lymphoma","volume":"21","author":"Bonvini","year":"2007","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.13089","article-title":"Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive WP-restricted burkitt lymphoma and lymphoblastoid cell lines","volume":"167","author":"Hui","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"36573","DOI":"10.1074\/jbc.M802968200","article-title":"Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained ERK activation and C-FOS","volume":"283","author":"Vaysberg","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2217\/fon.09.53","article-title":"Role of the Epstein-Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma","volume":"5","author":"Morris","year":"2009","journal-title":"Future Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1158\/1535-7163.MCT-12-0811","article-title":"Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus","volume":"12","author":"Hui","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"10029","DOI":"10.1128\/JVI.02241-06","article-title":"Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with ebv-transformed B cells","volume":"81","author":"Zou","year":"2007","journal-title":"J. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1128\/JVI.01096-06","article-title":"Epstein-Barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in burkitt\u2019s lymphoma cells","volume":"81","author":"Leao","year":"2007","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10709","DOI":"10.1128\/JVI.79.16.10709-10717.2005","article-title":"Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B and -3C expression in burkitt\u2019s lymphoma cells and with increased resistance to apoptosis","volume":"79","author":"Kelly","year":"2005","journal-title":"J. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2010-05-285791","article-title":"Lymphomas differ in their dependence on Epstein-Barr virus","volume":"117","author":"Vereide","year":"2011","journal-title":"Blood"},{"key":"ref_66","first-page":"2523","article-title":"Immunochemical analysis of the interaction of p53 with MDM2\u2014Fine mapping of the MDM2 binding site on p53 using synthetic peptides","volume":"9","author":"Picksley","year":"1994","journal-title":"Oncogene"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"MDM2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1182\/blood-2011-01-332379","article-title":"Bortezomib induction of C\/EBP\u03b2 mediates Epstein-Barr virus lytic activation in burkitt lymphoma","volume":"117","author":"Shirley","year":"2011","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/nm.1864","article-title":"Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors","volume":"14","author":"Fu","year":"2008","journal-title":"Nat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"13069","DOI":"10.1073\/pnas.1002985107","article-title":"Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma","volume":"107","author":"Sarosiek","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"13052","DOI":"10.1038\/s41598-017-13533-7","article-title":"Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy","volume":"7","author":"Granato","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.18632\/oncotarget.6601","article-title":"Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib","volume":"7","author":"Hui","year":"2015","journal-title":"Oncotarget"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/ijc.24945","article-title":"Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death","volume":"126","author":"Hui","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/ijc.27439","article-title":"Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma","volume":"131","author":"Hui","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Choi, C.K., Ho, D.N., Hui, K.F., Kao, R.Y., and Chiang, A.K. (2015). Identification of novel small organic compounds with diverse structures for the induction of Epstein-Barr virus (EBV) lytic cycle in EBV-positive epithelial malignancies. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0145994"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ijc.29698","article-title":"Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir","volume":"138","author":"Hui","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.18632\/oncotarget.14365","article-title":"Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+ T cell antitumor function","volume":"8","author":"Pellom","year":"2017","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1158\/2326-6066.CIR-16-0102","article-title":"Bortezomib relieves immune tolerance in nasopharyngeal carcinoma via STAT1 suppression and indoleamine 2,3-dioxygenase downregulation","volume":"5","author":"Jiang","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-03-0561","article-title":"Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors","volume":"10","author":"Pei","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0609.2007.00995.x","article-title":"Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma","volume":"80","author":"Heider","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1600-0609.2009.01239.x","article-title":"Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma","volume":"82","author":"Heider","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2003-03-0737","article-title":"The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in BCR\/ABL+ cells sensitive and resistant to STI571","volume":"102","author":"Yu","year":"2003","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/leu.2009.41","article-title":"The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia\/lymphoma cells apoptosis","volume":"23","author":"Zhang","year":"2009","journal-title":"Leukemia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s10495-007-0063-y","article-title":"SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor bortezomib","volume":"12","author":"Emanuele","year":"2007","journal-title":"Apoptosis"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jtcvs.2004.07.010","article-title":"Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species","volume":"128","author":"Denlinger","year":"2004","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1464-410X.2011.10533.x","article-title":"Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically","volume":"109","author":"Sato","year":"2012","journal-title":"BJU Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1182\/blood-2008-08-174797","article-title":"Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: A mechanism for synergy in leukemia cells","volume":"113","author":"Miller","year":"2009","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1158\/0008-5472.CAN-05-2961","article-title":"Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells","volume":"66","author":"Nawrocki","year":"2006","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4161\/cc.3.5.824","article-title":"The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA)","volume":"3","author":"Marks","year":"2004","journal-title":"Cell Cycle"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1002\/ijc.28924","article-title":"Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism","volume":"135","author":"Hui","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1002\/jcb.23303","article-title":"Reactive oxygen species-mediated endoplasmic reticulum stress and mitochondrial dysfunction contribute to polydatin-induced apoptosis in human nasopharyngeal carcinoma CNE cells","volume":"112","author":"Liu","year":"2011","journal-title":"J. Cell Biochem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.canlet.2010.03.008","article-title":"Reactive oxygen species-mediated endoplasmic reticulum stress and mitochondrial dysfunction contribute to cirsimaritin-induced apoptosis in human gallbladder carcinoma GBC-SD cells","volume":"295","author":"Quan","year":"2010","journal-title":"Cancer Lett."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1089\/jmf.2011.2024","article-title":"Platycodin D induces reactive oxygen species-mediated apoptosis signal-regulating kinase 1 activation and endoplasmic reticulum stress response in human breast cancer cells","volume":"15","author":"Yu","year":"2012","journal-title":"J. Med. Food"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/blood-2007-12-130823","article-title":"Myc regulates aggresome formation, the induction of NOXA and apoptosis in response to the combination of bortezomib and SAHA","volume":"112","author":"Nawrocki","year":"2008","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0891-5849(97)00007-5","article-title":"Photo-oxidative disruption of lysosomal membranes causes apoptosis of cultured human fibroblasts","volume":"23","author":"Brunk","year":"1997","journal-title":"Free Radic. Biol. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/sj.cdd.4402233","article-title":"Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells","volume":"15","author":"Chen","year":"2008","journal-title":"Cell Death Differ."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/ars.2006.8.152","article-title":"Oxidative stress and autophagy","volume":"8","author":"Kiffin","year":"2006","journal-title":"Antioxid. Redox. Signal"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"33568","DOI":"10.1074\/jbc.M114.599480","article-title":"The anticancer agent Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (DP44MT) overcomes prosurvival autophagy by two mechanisms: Persistent induction of autophagosome synthesis and impairment of lysosomal integrity","volume":"289","author":"Gutierrez","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1038\/onc.2015.450","article-title":"Oxidative stress enables Epstein-Barr virus-induced B-cell transformation by posttranscriptional regulation of viral and cellular growth-promoting factors","volume":"35","author":"Chen","year":"2016","journal-title":"Oncogene"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Huang, S.Y., Fang, C.Y., Wu, C.C., Tsai, C.H., Lin, S.F., and Chen, J.Y. (2013). Reactive oxygen species mediate Epstein-Barr virus reactivation by N-methyl-N\u2032-nitro-N-nitrosoguanidine. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0084919"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/JVI.05648-11","article-title":"Changes in the nasopharyngeal carcinoma nuclear proteome induced by the EBNA1 protein of Epstein-Barr virus reveal potential roles for ebna1 in metastasis and oxidative stress responses","volume":"86","author":"Cao","year":"2012","journal-title":"J. Virol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1128\/JVI.77.2.999-1010.2003","article-title":"EBNA3A association with RBP-J\u03ba down-regulates c-myc and Epstein-Barr virus-transformed lymphoblast growth","volume":"77","author":"Cooper","year":"2003","journal-title":"J. Virol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1128\/JVI.02279-10","article-title":"EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5","volume":"85","author":"Saha","year":"2011","journal-title":"J. Virol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.onc.1210668","article-title":"Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor BIM: Clues to the pathogenesis of burkitt\u2019s lymphoma","volume":"27","author":"Anderton","year":"2008","journal-title":"Oncogene"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Paschos, K., Smith, P., Anderton, E., Middeldorp, J.M., White, R.E., and Allday, M.J. (2009). Epstein-Barr virus latency in B cells leads to epigenetic repression and CPG methylation of the tumour suppressor gene BIM. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000492"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1097-2765(02)00443-4","article-title":"CTBP, an unconventional transcriptional corepressor in development and oncogenesis","volume":"9","author":"Chinnadurai","year":"2002","journal-title":"Mol. Cell"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1128\/JVI.73.7.5688-5697.1999","article-title":"Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription","volume":"73","author":"Radkov","year":"1999","journal-title":"J. Virol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1128\/JVI.77.7.4261-4272.2003","article-title":"Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors MSIN3A and NCOR in human B-cell lines","volume":"77","author":"Knight","year":"2003","journal-title":"J. Virol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrc2169","article-title":"CDC25 phosphatases in cancer cells: Key players? Good targets?","volume":"7","author":"Boutros","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.semcancer.2006.03.002","article-title":"14\u20133-3 proteins in cell cycle regulation","volume":"16","author":"Hermeking","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2217\/epi.12.52","article-title":"A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, istodax\u00ae)","volume":"4","author":"Harrison","year":"2012","journal-title":"Epigenomics"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","article-title":"Approval summary for bortezomib for injection in the treatment of multiple myeloma","volume":"10","author":"Bross","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-9966-27-13","article-title":"Implication of heme oxygenase-1 in the sensitivity of nasopharyngeal carcinomas to radiotherapy","volume":"27","author":"Shi","year":"2008","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"Food and drug administration approval: Carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","article-title":"Ixazomib: First global approval","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/9\/11\/352\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:50:38Z","timestamp":1760208638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/9\/11\/352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":118,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11]]}},"alternative-id":["v9110352"],"URL":"https:\/\/doi.org\/10.3390\/v9110352","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,21]]}}}